Medicare's Transforming Episode Accountability Model is projected to save $46.6 million by 2030, with safety-net hospitals ...

Conclusions: Cancer costs for employers are not uniformly increasing, but instead, shifting based on market competition and therapeutic innovation. Where costs are rising, they are driven by novel ...

Employer-mandated high-deductible health plan enrollment was not associated with reduced use of oral targeted anticancer ...

The prevalence of diabetes mellitus (DM) increased by 49% between 1990 and 2000, reaching nearly epidemic proportions. In 2010, DM (type 1 or 2) was estimated to affect nearly 30% (10.9 million) of ...

CMS is adding value-based care (VBC) risk faster than many providers can build the data and tech capacity they need to ...

Gray market peptides cause vague symptoms patients may not disclose or link, so serious harms can go unnoticed until late, ...

Goad, PharmD, MPH, of Chapman University explains why pharmacists are trusted, accessible sources for COVID-19 vaccine ...

MA-to-MA switching among dually eligible beneficiaries rose sharply from 2016 to 2022, AJMC study author Grace Mackleby, PhD, ...

Telitacicept has the first regulatory approval for Sjögren disease (China), while global phase 3 programs aim to support ...

Weekly survodutide 3.6 mg/6.0 mg achieved up to 13.1% mean weight loss at week 76 versus 3.1% with placebo, meeting ...

FDA movement of peptides toward 503A bulks listing advanced despite internal scientific objections citing absent human ...

LIBERTY met all primary/secondary endpoints, with lower 6-day TEAEs/ISRs/hypersensitivity (56.5% vs 91.4%) and systemic AEs ...